Overview
This book provides a comprehensive introduction to statistical methods for designing early phase dose-finding clinical trials. It will serve as a textbook or handbook for graduate students and practitioners in biostatistics and clinical investigators who are involved in designing, conducting, monitoring, and analyzing dose-finding trials. The book will also provide an overview of advanced topics and discussions in this field for the benefit of researchers in biostatistics and statistical science. Beginning with backgrounds and fundamental notions on dose finding in early phase clinical trials, the book then provides traditional and recent dose-finding designs of phase I trials for, e.g., cytotoxic agents in oncology, to evaluate toxicity outcome. Included are rule-based and model-based designs, such as 3 + 3 designs, accelerated titration designs, toxicity probability interval designs, continual reassessment method and related designs, and escalation overdose control designs. This bookalso covers more complex and updated dose-finding designs of phase I-II and I/II trials for cytotoxic agents, and cytostatic agents, focusing on both toxicity and efficacy outcomes, such as designs with covariates and drug combinations, maximum tolerated dose-schedule finding designs, and so on.
Full Product Details
Author: Takashi Daimon ,
Akihiro Hirakawa ,
Shigeyuki Matsui
Publisher: Springer Verlag, Japan
Imprint: Springer Verlag, Japan
Edition: 1st ed. 2019
Weight: 0.454kg
ISBN: 9784431555841
ISBN 10: 4431555846
Pages: 133
Publication Date: 31 May 2019
Audience:
College/higher education
,
Professional and scholarly
,
Postgraduate, Research & Scholarly
,
Professional & Vocational
Format: Paperback
Publisher's Status: Active
Availability: Manufactured on demand
We will order this item for you from a manufactured on demand supplier.
Reviews
The book under review is intended to serve as a brief handbook for graduate students and biostatistics, as well as for oncologists who are involved in the analysis of methods for developing optimal doses for treating cancer in the early stages. (Fatima T. Adylova, zbMATH 1427.92001, 2020)
“The book under review is intended to serve as a brief handbook for graduate students and biostatistics, as well as for oncologists who are involved in the analysis of methods for developing optimal doses for treating cancer in the early stages.” (Fatima T. Adylova, zbMATH 1427.92001, 2020)
Author Information
Takashi Daimon, Department of Biostatistics, Hyogo College of MedicineAkihiro Hirakawa, Center for Advanced Medicine and Clinical Research, Nagoya University Graduate School of MedicineShigeyuki Matsui, Department of Biostatistics, Nagoya University Graduate School of Medicine
